title: Antivascular Endothelial Growth Factor Monotherapy for Choroidal Neovascularization Associated With Retinochoroidal Coloboma: Case Series.
abstract: OBJECTIVE
  This study aimed to report the outcomes of antivascular endothelial growth factor (anti-VEGF) monotherapy for choroidal neovascularization (CNVM) associated with retinochoroidal coloboma (RCC).
  
  
  METHODS
  A retrospective case series.
  
  
  METHODS
  This was a case series of 3 eyes with CNVM associated with RCC that presented to the LV Prasad Eye Institute, Hyderabad, India, between January 2006 and January 2014. Reported data included demographics, preoperative details (symptoms, duration of symptoms, and visual acuity), treatment methods, and postoperative details (visual acuity, follow-up, and recurrence). These data were compared with 9 other cases previously reported in the literature.
  
  
  RESULTS
  Three eyes of 3 patients (2 females and 1 male) were included, with a mean age of 18.3 years (range, 2-32 years). The preoperative best corrected visual acuity ranged from 20/540 to 20/100. All 3 eyes were treated with intravitreal bevacizumab injections. The mean number of injections was 2.0 (range, 1-3) and mean duration of follow-up was 12 months (range, 4-24 months) with no recurrence. The best corrected visual acuity at the last follow-up was improved, ranging from 20/310 to 20/60.
  
  
  CONCLUSIONS
  In view of good treatment outcomes with no recurrence and a lesser number of injections, anti-VEGF monotherapy could be considered as treatment for coloboma-associated CNVM.
authors.affiliation: From the *University of North Carolina School of Medicine, Chapel Hill, NC; and †Srimati Kanuri Santhamma Centre for Vitreoretinal Diseases, LV Prasad Eye Institute, Hyderabad, Telangana, India.
authors.forename: Sailaja
authors.initials: S
authors.lastname: Bondalapati
authors.forename: Subhadra
authors.initials: S
authors.lastname: Jalali
authors.forename: Jay
authors.initials: J
authors.lastname: Chhablani
mesh_terms: D000293:Adolescent; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002829:Choroid / Q000002:abnormalities*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D003103:Coloboma / Q000150:complications*; D005260:Female; D006801:Humans; D007194:India; D058449:Intravitreal Injections; D008297:Male; D012160:Retina / Q000002:abnormalities*; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab